observ orlando fairi tale ftsv
thing learn thing heard industri confer
server updat declin eas ramp competit weigh
hot dog revenu momentum continu profit ahead
frame catalyst increas target
take look expect readout tyvaso ild unituxin
read-through sanofi capit market day preview long-term dupix
guidanc eur depriorit praluent kevzara
updat r/r b-cell nhl respons rate
updat mcl efficaci car-t
confer call invit takeaway annual
focu advanc multipl myeloma car-t bispecif
like shape futur treatment landscap
manag healthcar facil
surpris bill law move forward provid oppos pbm
less cyclic busi model float dealer
public contain summari recent credit suiss research report bring notabl research attent full report summari
certif legal entiti disclosur inform statu non-u analyst equiti research disclosur click
observ orlando fairi tale
ftsv
increment detail registr md compani expect potenti bla file
earli base data on-going single-arm trial enhanc
trial random control trial design support full ex-u approv studi
estim enrol approxim patient power alpha
adapt design allow addit patient order establish potenti surviv benefit
primari studi cr durabl cr near-term focu continu
higher risk md ftsv indic may explor magrolimab lower risk and/or r/r md
addit potenti expans aml earli data patient promis
compani continu enrol patient mutat think md opportun add
support stock believ compani take right step continu
develop program area high unmet need
proof-of-concept establish nhp data present show
well-toler preclin anim model combo
deplet hematopoiet stem cell non-human primat without deplet matur immun
cell data provid proof-of concept relev anim model intend use
first-in-human studi establish dose/safeti expect start second develop
stage program explor autolog transplant gene
correct cell set recal compani recent announc partnership bluebird bio
model updat increas target price think clinic
updat de-risk md opportun suggest potenti upsid opportun
magrolimab addit set time increas po md
ad valu pipelin account mds/aml option rais
 weight tp base addit clinic valid increas
scarciti valu magrolimab risk thesi clinical/regulatori competit
date product utc date dissemin utc
thing learn thing heard
last week host investor meet compani present annual credit suiss
industri confer florida also host investor field trip area start
week note summar takeaway confer field trip also provid
updat investor sentiment posit across sector compani level
cycl commentari outlook commerci aerospac name tend toward bullish
side particularli among aftermarket supplier continu see healthi demand environ
refer debacl either neutral posit near-medium term
aftermarket outlook increas matur fleet profil indic one key
driver aftermarket strength next sever year commentari defens
contractor remain bullish hardwar servic name continu articul multi-
year growth stori remain confid outgrow budget next sever
year though suspect least partial function outlay gap prior budget
well intern demand contractor spoke appear comfort
financi perspect prospect lengthi continu resolut
investor sentiment investor sentiment commerci aerospac group remain broadli
construct particularli bullish sentiment tilt discuss toward
regard investor see upsid rang recertifi
though mani remain frustrat compani messag strategi see boe novemb
press releas associ recertif time predict counterproduct buysid
expect recertif appear slip januari believ
increment multi-billion dollar charg may need sinc return servic least three
month later contempl prior charg juli defens lean
bearish group tend focu prospect recoveri broader industri sector
would theoret drive unfavor sector rotat defens well
elev risk defens elect bullish gener argu
revers see continu risk industri macro point equival even higher
elect risk area market financi healthcar said sinc
investor dont fulli confid view macro trend elect resolv
also dont know feel defens either mani investor seem sit fenc
without firm view group compani level mani wonder
drive lhx under-perform past month gener overarch question
stock center right yield sentiment toward bullish
heard time mani see upsid potenti street shipbuild margin next year
concern regard gd given compani yet appear
receiv payment work track vehicl saudi arabia
model updat decreas capital-expenditure estim drive increas
tp risk includ budget risk execut fix price contract
date product utc date dissemin utc
profit ahead
ebitda million ahead consensu million chwi ebitda
million exceed million estim higher revenu profit importantli
chwi up revenu guidanc call
ebitda million midpoint million previous vs consensu
million impli stronger oper experi rais ebitda
million million ep move reflect latest
upsid better profit experi balanc year target price stand
maintain posit bia stock convict chwi faster-than-industri
growth meaning profit margin ramp
plan estimate impress growth activ custom vs estimate net
sale per activ custom vs estimate slightli plan autoship sale
increas rise sequenti gross margin expand bp y/
bp better plan admin expens rose bp bp plan advertis
fell bp bp plan ebitda margin expand whop bp y/i bp
ahead plan post net loss million vs estimate million flow
million vs net cash use million cash reserv stand million
share rise attract valuat share sinc june ipo
close price vs chwi share regain momentum latest
evid continu robust custom sale growth share current trade
ev/sal de minimispremium list price notabl discount
broader peer group e-commerc retail platform anim health product servic
well healthcar servic compani fulli reflect rapid growth
trajectori long-term profit opportun risk includ competit consum spend shift
advertis spend ownership structur
date product utc date dissemin utc
adjust estim adjust su cfp earn estim vs
consensu lower estim reflect wider wc diff weaker base
refin crack expect total volum vs street
adjust estim adjust su cfp earn estim vs
consensu estim ffo capital-expenditure leav
model dividend hike leav buyback
model buyback wider wc diff would headwind oil sand
segment tailwind refin estim also reflect slightli higher opex guidanc fort
valuat target price base sum-of-the-part methodolog ebidax
multipl oil sand ebidax
multipl less corpor expens debt equat
risk downsid risk includ lower crude price wider wti-syncrud spread wider
wti-wc spread reliabl issu syncrud
date product utc date dissemin utc
price month
frame catalyst increas target
ralli ytd vs ytd thought worthwhil
sale canada distribut vivint smart home/
spacexpect close similar underli econom
smart home/secur space also analyz five compani paid special
dividendpayout direct similar market capto gener rule
stock price slip day declar ralli day
payment rel share price out-performance vs averag
day payment special dividend also introduc ebitda
boost tp ebitda
upcom yield /share special dividend sale
canada distribut vivint smart home/mosa spacexpect close
similar underli econom smart home/secur space vivint
offer valuat ebitda calcul given publicli disclos data
within investor present ex-sac basi vs model compar
special dividend play slip day declar ralli
day paymentcompani similar pay-out ratio percent market cap adt
cse recogn company-specif factor dataset use show rel
share price out-performance vs averag day payment
recent re-affirmed guidanc despit canada salesuggest could
boost guidanc without canada divestitur telu rate
outperform amid robust growth commerci organ growth although monitor
attrit trend higher qoq yoy dealer account remain
headwind addit free cash flow could impact on-going convers cost lack
contribut canada post-sal
tp prior ev/ebitda versu since-ipo rang averag
sinc ipo risk thesi includeincreas attrit leverag
date product utc date dissemin utc
lower estim invest lower ebitda
y/i y/i ep y/i y/i due
clarif launch peacock estim loss ebitda
loss relat launch broadband itali upgrad custom equip
lower cabl network ebitda nbcu affili renew time
broadband still stronger longer offset news growth
hamper invest manag indic today broadband net add y/i
rais net add estim vs
trend cabl re-affirmed expect revenu growth ebitda growth
thesi intact comcast manag consist invest long-term growth
extent signal time peacock invest though clarifi
amount first time believ share inexpens rel peer especi given
qualiti compani asset investor look forward like return share
repurchas post balanc sheet refresh cabl oper momentum cabl cash
flow improv continu time nbcu/ski invest ration
help hold busi
valuat comcast trade price-to-earnings p/fcf ev/ebitda dcf-
disintermedi competit reengag shift regulatori climat long-term mobil
broadband competit poor deploy capit
date product utc date dissemin utc
price month
take look expect
readout tyvaso ild unituxin sclc
increas distinct readout reflect valuat investor
expect outperform thesi incorpor valu uthr non-ralinepag pipelin
program see expect readout tyvaso ph ild increas trial
unituxin r/r sclc distinct trial low downsid risk event case distinct
like free call option posit clinic catalyst limit past year
expect success either studi could greater impact share price
expect npv contribut
uncertainti program optimist success ph ild
sclc carri greater upsid potenti see increas distinct lower
typic po trial case underli mechan action support
rational success pauciti support evid exist mani question remain
unansw addit program target challeng patient popul heterogen
interstiti lung diseas ild relapsed/refractori small cell lung cancer sclc
estim success increas would gener increment tyvaso revenu
translat fulli de-risk increment npv unituxin uptak sclc would
depend toler efficaci profil major unknown market share penetr
us could yield opportun worth potenti upsid uptak
assumpt depend qualiti data
reiter outperform thesi juli upgrad note propos driver
support upsid potenti share potenti less aggress gener uptak
recognit steadi tyvaso/orenitram cash flow potenti strong tyvaso tail valu
ralinepag potenti best-in-class profil potenti share buyback potenti
activism/m seen partial recoveri recent week continu see
upsid potenti rel recent channel check east coast west coast
support thesi note sc remodulin share particularli resili
could reinforc approv novel sc pump
date product utc date dissemin utc
price month
read-through sanofi capit market
eur depriorit praluent kevzara
dupix key pillar sanofi go forward strategi advanc sanofi capit market
day tomorrow new ceo paul hudson unveil strateg prioriti organ
colleagu fulli cover event provid key read-
through coverag regeneron notabl mr hudson focus growth
dupix identifi key driver forecast eur end-us peak sale significantli
ahead forecast usd peak encourag sanofi priorit dupix
includ addit potenti indic prurigo nodulari bullou pemphigoid chronic
spontan urticaria allerg bronchopulmonari aspergillosi plan phase trial
announc novemb echo commentari regeneron manag recent
healthcar confer cfo specif call potenti dupix asthma
launch remain earli ou territori
praluent kevzara depriorit sanofi stop diabet
cardiovascular area also encourag sanofi decis depriorit commerci
invest praluent kevzara could lead better profit antibodi
jvbenefit regeneron sanofi collabor revenu line item give anem sale
asset surpris mr hudson right-siz resourc deploy
mention restructur partnership antibodi i/o pr suggest
sanofi plan restructur partnership regeneron await addit color
commentari sanofi manag partnership regeneron get sens
dupix libtayo remain high prioriti asset sanofi
see sanofi updat increment posit regeneron given long-term
expect dupix like enhanc profit antibodi jv focu
oncolog libtayo anchor asset view
date product utc date dissemin utc
price month
updat r/r b-cell
nhl respons rate toxic
attend on-going american societi hematolog meet orlando
herein pass along thought new data present regeneron r/
 b-nhl abstract slide found phase trial progress poster
found slide found gener like saw
believ could eventu use combin therapi
overal remain encourag data updat r/r b-nhl
patient expand data present eha june first data weve
seen higher dose mg cohort notabl patient dose mg higher
orr cr rate highlight observ compel efficaci
dlbcl patient previous fail t-cell therapi orr cr
patient treat mg dose higher higher respons rate seen r/r fl
patient grade median fl patient month among patient
opportun assess week across board efficaci data suggest good
antitumor activ heavili pre-treat patient r/r diseas note mcl gilead kte-
higher orr cr respect per data present
meet like rel efficaci dlbcl good respons rate even car-t
failur dlbcl patient on-going data cut
safeti reflect advanc patient accept neuro-tox note
infect rate somewhat high patient die studi major
due progress diseas reason includ gastric perfor cardiac arrest lung
infect pneumonia data cut addit patient die tumor lysi syndrom
death expect trial involv advanc patient overli concern step-up
dose support care help mitig irr/cr event investig character
safeti profil accept high mg dose wkli
date product utc date dissemin utc
price month
updat mcl
efficaci car-t therapi
attend on-going american societi hematolog meet
orlando herein pass along thought new data present gilead
r/r mantl cell lymphoma trial abstract pleas ask us
efficaci data compel r/r mcl patient still commerci concern remain given
challeng car-t therapi real-world overal think data
compel overal respons rate orr includ patient achiev
complet respons cr believ car-t therapi continu face commerci
challeng encourag rel high respons rate seen trial
durabl look good well median dor yet reach median follow-up
month patient includ previous cr remiss among
first dose medial follow month rang
remain remiss patient median prior line therapi includ
btk intoler broader context think data support regulatori
approv car-t remain commerci challeng data matur novel
therapi mcl bispecif could see less usag car-t therapi given rel
difficulti resourc intens administ manufactur
safeti look good given later line treatmentno grade observ
consist car-t therapi nearli patient experi sort patient
cytokin releas syndrom patient manag tocilizumab manag
corticosteroid unsur profil would allow administ
outpati out-pati like set given high rate character safeti
profil consist direct car-t therapi aggress nhl
gilead expect file us fda bla ema
date product utc date dissemin utc
price month
less cyclic busi model float dealer
follow-up recent publish research thought worthwhil
assess believ human capit manag hcm sectormost notabl
payxi well posit outperform later cycl event downturn
note focu believ compani less cyclic busi
model last downturn given less leverag interest fund held client
lower rate environmentand
divestitur cyclic dealer servic total revenu busi
part approach base view market award
healthier multipl less cyclic busi time addit adp model
cloud saas-bas today help drive higher increment margin
recur revenu healthier multipl well said recogn
immun overal macro environ
busi model benefit cloud saas-bas servicesrel histori
us hcm client cloud revenu complet
down-market migrat mid-market follow us hcm
client cloud-bas platform revenu drove mainten spend
save compound-annual-growth-rate portion shift innov spend
prefer payrol stock payxwhich believ better posit late cycl
downturn rel prior cycl fulli discount vs staf search
gener underperform late-cycl recessionari environ past cycl staf
coverag pull back averag vs
tp epsv three-year rang averag
late-cycl averag risk thesi includecompetit saas-bas
hcm provid impact share less-than expect margin expans
date product utc date dissemin utc
price month
price month
momentum continu meet convers verizon manag
confer present believ wireless momentum continu consist
result verizon ration black friday market plan lean
acquisit iphon bogo quit well see effici benefit
disney subscrib well ahead expect believ subscrib
launch day one-third unlimit subscrib partnership like
extend view still lose less market share cabl mvno remain
net posit revenu
initi track verizon expect handset mmwave dss
capabl averag smartphon handset cost lower despit inclus
chipset dynam spectrum share dss remain track though management
indic get enough credit headroom leadership lte
go market front verizon announc partnership amazon aw servic co-host cloud
game edg could yield differenti servic offer next fall gen
equip oper higher power goe farther penetr build easier easier self-
setup track
strategi come focu consum see lift speed vs lte
low-to-mid band seem vz like hold nationwid mobil roll-out offer
differenti servic expect fall dss implement
coverag strand push main fiber run broader higher capac
mmwave coverag high traffic area handset broadli avail incl mid-tier
price potenti icon phone launch next-gen
launch amazon cloud game kick whether vz offer superior
stream connect high traffic area like stadium train station drive share gain
valuat vz trade ep ebitda cheaper ts impli wireless
valuat view dcf-base price target dividend yield pay-out
date product utc date dissemin utc
attend beverag digest futur smart seminar ny attend industri
substanti capit invest soft drink market first
time mani year drive better short/medium term growth versu long-term
trend previous challeng market
nearli particip expect above-infl price price environ remain
ration see risk price war discount sever bottler mention benefit
new analyt one help limit wast discount well revenu growth
ko neutral tp top-line growth like remain year
compani grow fastest rate decad driven primarili strength core
carbon soft drink csd develop market
signific opportun develop market lower per capita consumpt portfolio
expans beyond colas/csd coffe across groceri foodservic ready-to-drink
compani cultur adopt greater flexibl focu go consum want
long runway partnership monster potenti beyond energi drink
collabor bottl network rise tide system sever bottler
acknowledg learn bottler also implement chang
exampl autom lesson rey global revenu manag strategi arca
bottler invest heavili newli acquir market
year under-invest coke new bottler invest heavili includ new facil
improv reach execut also beneficiari
new analyt support better price revenu growth manag custom connect
receiv bottler offer posit commentari compar convers last year far
skeptic mr laguarta becam ceo oct
hear posit commentari heard beverag
busi year mr laguarta spend heavili brand capital-expenditure brought
lot energi compani
put capit market help close gap uniqu packag size
compani lag mini can
date product utc date dissemin utc
ramp competit weigh
server updat idc report server industri revenu y/i
modest improv vs drop still mark first back-to-back
declin sinc sinc pace unit declin eas vs earlier year
y/i vs asp declin acceler y/i
quarter vs overal commentari hardwar vendor
coverag univers continu suggest challeng backdrop enterpris spend
on-going digest well above-trend compound macro uncertainti drive
decis delay larg purchas increasingli concern industri
aggress competitor rapidli repric fall compon cost name dram
end custom margin remain key risk adjust server revenu est
expect tradit enterpris demand lag hyperscal trend next year
takeaway pressur mount fell y/i
acceler sharpest drop sinc consist
commentari increasingli aggress price especi larg deal
lower commod cost push expect y/i declin dram remain
headwind unit continu declin pace slow
y/i vs prior quarter sequenti growth
season average hyperscal demand appear stabil use odm direct
rough proxi unit shipment rose y/i vs declin inde
cloud revenu y/i third quarter enterpris demand remain soft
ex-odm unit y/i outpac drop broader market
similarli asp total revenu trend window server primarili sold enterpris
deterior trend linux server improv modesti western european
demand deterior notic units/revenu y/i vs y/i
unit/revenu trend remain improv apac/u mainfram revenu fell
y/i ahead new launch late sept
vendor implic within coverag greatest exposur server
revenu follow sale under-perform
market unit/rev share y/i incl unit/rev
share y/i declin second quarter
row y/i idc report total unit y/i estim
core ex-tier incl china unit fell modest low singl digit rate oct
look ahead expect server asp headwind weigh revenu margin
also lost share unit/rev share y/i
declin outpac market y/i held better despit greater
competit larg enterpris deal dell decis avoid transitori unprofit share
like play role server price also remain key risk ahead management
expect competit potenti commod cost inflat return margin level
date product utc date dissemin utc
annual cs industri confer
call jointli host european capit good electr equip multi-
industri analyst present key takeaway annual credit suiss industri
date product utc date dissemin utc
focu advanc multipl
myeloma car-t bispecif like
wind come away increment posit regeneron bispecif
platform particularli anti-bcma asset see take data earli
day multipl myeloma await addit data look differenti term
safeti efficaci durabl consid assign signific valu program
howev believ ampl commerci opportun given challeng
administr high cost therapi particularli patient inelig continu
progress treatment believ novel oncolog platform offer opportun upsid
littl valu includ current estim earli natur data prevent us
greater convict
approach multipl myeloma jnj continu impress abstract
addit data studi patient r/r mm present monday
recal result orr progress free month
therapi data studi present monday reinforc posit view
program ident construct drove orr cr
rate median month one patient progression-fre month safeti
consist anti-bcma therapi cytokin
releas syndrom remain frequent advers event rate
respect overal think data impress
orr nearli year better therapi weve seen clearli valid anti-
bcma approach r/r mm though note trail bmy/blu expect approv
differ across trial limit compar
bristol/bluebird bcma car-t data encourag abstract monday
bristol partner bluebird announc updat phase data patient r/r mm
data cut-off patient low-dos cell cohort matur data
achiev orr cr median durat respons month data among
two higher dose cohort remain earli mid-dos month
follow-up high-dos respond month follow-up
much buzz around jnj program think bristol/ bluebird data promis
particular data higher-dos cohort matur
anti-bcma market like room sever modal host dinner sunday
expert physician discuss unfold data meet see expert
dinner takeaway overal expert believ substanti opportun new
modal mm beyond expert indic off-the-shelf therapi adc
bispecif like uptak commun set think gsk belantamab
mafodotin efficaci enough consid use ocular toxic ultim manag via
steroid eye drop mean leav thrombocytopenia ae manag
around bispecif promis data still earli would like visibl
ae administr profil candid clear winner
moment physician indic manufactur reliabl overal safeti key driver
commerci success base car-t experi
date product utc date dissemin utc
manag healthcar facil
oppos pbm provis includ
surpris bill compromis reach dec hous committe announc
reach bipartisan agreement senat help committe surpris bill
previous hous committe pass bill benchmark payment rate
independ disput resolut idr process avail claim greater
contrast senat help committe pass bill allow benchmark
payment rate idr process dec senat help committe staff releas addit
detail note dollar threshold idr process appeal particular claim
legisl includ provis pbm transpar telehealth
potenti time dc consult note announc came senat
alexand rep pallon rep walden three six key congression player
issu virtu committe chair rank member committe help
committe hous way mean committe three key player
comment hous speaker nanci pelosi senat major leader mitch mcconnel also
comment consult expect propos get momentum quickli would
ad onto one end year appropri bill congress hope send presid
trump decemb like labor hh educ appropri bill could
get packag defens appropri bill appropri process sidelin
surpris bill could move forward stand-alone bill consult believ would
wors odd move forward thing consid consult think could see bill
enact late year earli white hous issu statement monday
support effort ask congress send legisl presid trump year
fah ac alreadi express opposit compromis given benchmark
approach main basi payment determin out-of-network claim provid believ
approach would give much leverag insur rel hospit mani
servic would fall threshold
impact surpris bill provis coverag met last week
hq support govern rate-set benchmark said surpris bill
legisl major threat econom though could neg downstream effect
physician partner held out-of-network around revenu
typic relat contract negoti possibl greatest threat md
benchmark approach insur may game system cancel contract pay
above-benchmark rate caus insur pay lower benchmark rate time
could pressur benchmark rate lower could creat cycl lower lower payment
rate clear whether would happen practic whether provid could similarli
influenc benchmark cancel below-benchmark contract rate
date product utc date dissemin utc
what new morn xerox publish slide present outlin case
propos acquisit hp inc compani sharehold includ detail cost synergi
estim potenti revenu upsid recal xerox first made unsolicit offer
unanim reject board cite concern
valuat pro-forma leverag opportun leverag balanc sheet valu
creation result xerox take bid directli sharehold continu think
industri consolid make sens view xerox hp portfolio larg complimentari
primarili consum vs xerox primarili limit overlap see opportun
signific cost takeout two compani combin bolster morn
present preliminari pro forma estim result ep fcfp accret
 assum cost synergi base
net cost synergi achiev evenli three year leverag remain key
hurdl pf net debt ltm adj ebitda incl full synergi run-rat per management
propos structur though strong compani provid signific capac
takeaway present xerox detail run-rat net cost
synergi achiev within month across rang procur manufactur
corpor function repres compani combin total cost base
combin print cost base manufactur it/r largest identifi bucket
opportun manag target wed note xerox
current management team solid record cost save sinc take deliv
gross save month project effici cost per
gross save synergi cadenc weight toward year expect
realiz year year manag look drop
bottom line increment reinvest self-fund program xerox also
expect potenti revenu synergi year largest
opportun come cross-sel complementari product portfolio
other instal base addit opportun expand as-a-servic offer optim
gtm model expand sw servic leverag xerox fs see
opportun view revenu synergi far less certain sourc upsid xerox
believ combin entiti could maintain invest grade credit rate despit
leverag full run-rat synergi base propos deal structur see
increment after-tax debt cost estim impli rate base
new debt requir fund cash portion transact per cse
current dividend would maintain xerox target return
initi de-lever period like suspend buyback near term per cs
estim dividend payment base pro-forma share count excess
use debt repay xerox management estim leverag incl cost
date product utc date dissemin utc
